Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC is a research paper published in Cancer Discovery (2023). On theSindex it has a DataRank of 0.787. It has been cited 189 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.787
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: NIH/NCI 1R01 CA262469-01
NIH Clinical Center
Grant: T32-GM07019
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
National Institutes of Health
Grant: 5R01CA262469-04
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
National Institutes of Health
Grant: 5T32GM007019-13
CLINICAL THERAPEUTICS
Fields of Study
Keywords